

Series A Round

\$50mm

Initial Investment
Targets

8-12 Development
Stage Companies

Typical Investment

\$1mm - \$5mm

Real Estate
Acquisitions

3-5 Commercial
Properties

Fund Management

Chas Radovich
Chairman/ President

Paul Peterson
Director / VP

Dr. Greg Brown
Director

A Life Sciences Technology VC & Qualified Opportunity Zone Fund

Mission: To accelerate the commercialization of natural medicines that have demonstrated real world efficacy preventing and treating chronic health conditions to include: cancer, opioid addiction, PTSD, migraines, multiple sclerosis, and rheumatoid arthritis.

- Seed & Early-Stage Capital
- Active Management of Invested Companies
- Impact Investing
- Profitable Outcomes

"We've seen too many personal loved ones alive today because of these treatments not to do everything we can to bring this into the mainstream."

- Chas Radovich

Botanical Medicines

Leveraging our network and expertise in product testing, extraction, isolation, and production of patentable medicines, the Fund will invest in seasoned and passionate professionals and draw from universities and research institutions not susceptible to boom/bust cycles.

Probiotic Medicines

Recognizing human biome health is integral to overall health, our companies will develop, refine, and distribute targeted probiotics strains in the treatment of targeted illnesses and immune system enhancement.

Immunotherapy and Prevention

Currently developing a world-class Immunotherapy and Wellness Center to research, administer, and showcase to the world our portfolio companies' breakthroughs in immune system enhancement and post diagnosis treatment.

The Opportunity Zone Advantage

- Capital gains invested are deferred for 7 years
- Investments held over 10 years are capital gains tax free
- Shared incentives for a long-term outcome

Universal Labs Opportunity Fund, Inc.
4040 SE Cirrus Ave. McMinnville, OR 97128
www.UniversalLabsFund.com

Phone: 888.577.9357
Invest@UniversalLabsFund.com